[New Radiopharmaceuticals Based on Prostate-Specific Inhibitors of Membrane Antigen for Diagnostics and Therapy of Metastatic Prostate Cancer]
| Autor: | V M Petriev, Konstantin E. German, O P Vlasova, N B Epstein, Krilov Vv |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
PCA3
Oncology Glutamate Carboxypeptidase II Male medicine.medical_specialty Prostate cancer Pharmacokinetics Antigen Prostate Antigens Neoplasm Internal medicine Early Medical Intervention Glutamate carboxypeptidase II Biomarkers Tumor Medicine Humans Early Detection of Cancer Neoplasm Staging business.industry Therapies Investigational Cancer Prostatic Neoplasms General Medicine medicine.disease Prostate-specific antigen medicine.anatomical_structure Antigens Surface Radiopharmaceuticals business |
| Zdroj: | Europe PubMed Central |
| ISSN: | 0869-6047 |
| Popis: | About 10.7% cases of prostate cancer were registered in Russia in 2011 (40 000 patients). More than half of cancer cases were revealed in advanced (III–IV) stages when metastases inevitably developed quickly. Clinical problem of early diagnostics and treatment of metastatic prostate cancer is still not solved. Anatomical imaging techniques have low sensitivity and specificity for the detection of this disease. Metabolic visualization methods which use prostate specific antigen (PSA) as a marker are also ineffective. This article describes prostate-specific membrane antigens (PSMA) that are proposed as a marker for diagnostics and therapy of prostate cancer. The most promising PSMA-based radiopharmaceutical agent for diagnostics has been developed and clinically tested in the European countries. These pharmaceuticals are based on small peptide molecules modified with urea, and have the highest affinity to PSMA. Favorable pharmacokinetics, rapid accumulation in the tumor and rapid excretion from the body are beneficial features of these pharmaceuticals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|